JP2016508505A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016508505A5 JP2016508505A5 JP2015556421A JP2015556421A JP2016508505A5 JP 2016508505 A5 JP2016508505 A5 JP 2016508505A5 JP 2015556421 A JP2015556421 A JP 2015556421A JP 2015556421 A JP2015556421 A JP 2015556421A JP 2016508505 A5 JP2016508505 A5 JP 2016508505A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- compound
- formula
- syndrome
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 13
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 5
- 239000012453 solvate Substances 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 201000006417 multiple sclerosis Diseases 0.000 claims 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000015943 Coeliac disease Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 2
- 208000005777 Lupus Nephritis Diseases 0.000 claims 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 241000347391 Umbrina cirrosa Species 0.000 claims 2
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 claims 1
- 208000007815 Acquired Hyperostosis Syndrome Diseases 0.000 claims 1
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 208000026326 Adult-onset Still disease Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010001935 American trypanosomiasis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 208000022715 Autoinflammatory syndrome Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 208000005024 Castleman disease Diseases 0.000 claims 1
- 208000024699 Chagas disease Diseases 0.000 claims 1
- 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 208000007465 Giant cell arteritis Diseases 0.000 claims 1
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000001204 Hashimoto Disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 208000018208 Hyperimmunoglobulinemia D with periodic fever Diseases 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 1
- 206010021263 IgA nephropathy Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 claims 1
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 claims 1
- 102100036342 Interleukin-1 receptor-associated kinase 1 Human genes 0.000 claims 1
- 101710199015 Interleukin-1 receptor-associated kinase 1 Proteins 0.000 claims 1
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 1
- 208000000209 Isaacs syndrome Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 208000011200 Kawasaki disease Diseases 0.000 claims 1
- 208000000185 Localized scleroderma Diseases 0.000 claims 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims 1
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 claims 1
- 101710126825 NACHT, LRR and PYD domains-containing protein 3 Proteins 0.000 claims 1
- 206010072359 Neuromyotonia Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010034277 Pemphigoid Diseases 0.000 claims 1
- 201000011152 Pemphigus Diseases 0.000 claims 1
- 208000031845 Pernicious anaemia Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 201000004854 SAPHO syndrome Diseases 0.000 claims 1
- 201000010848 Schnitzler Syndrome Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 206010072148 Stiff-Person syndrome Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 241000223109 Trypanosoma cruzi Species 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 206010000269 abscess Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 208000004631 alopecia areata Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 208000027625 autoimmune inner ear disease Diseases 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 208000000594 bullous pemphigoid Diseases 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000002849 chondrocalcinosis Diseases 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 201000003631 narcolepsy Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 1
- 230000000737 periodic effect Effects 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 210000000106 sweat gland Anatomy 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 206010043207 temporal arteritis Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- -1 wherein Rd is H Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13154390 | 2013-02-07 | ||
| EP13154390.2 | 2013-02-07 | ||
| PCT/EP2014/000316 WO2014121931A1 (en) | 2013-02-07 | 2014-02-06 | Pyridazinone-amides derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016508505A JP2016508505A (ja) | 2016-03-22 |
| JP2016508505A5 true JP2016508505A5 (enExample) | 2017-03-09 |
| JP6483624B2 JP6483624B2 (ja) | 2019-03-13 |
Family
ID=47681772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015556421A Expired - Fee Related JP6483624B2 (ja) | 2013-02-07 | 2014-02-06 | ピリダジノン−アミド誘導体 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US9567320B2 (enExample) |
| EP (1) | EP2953944B1 (enExample) |
| JP (1) | JP6483624B2 (enExample) |
| KR (1) | KR102293952B1 (enExample) |
| CN (1) | CN104968658B (enExample) |
| AU (1) | AU2014214321B2 (enExample) |
| BR (1) | BR112015018663A2 (enExample) |
| CA (1) | CA2900431C (enExample) |
| DK (1) | DK2953944T3 (enExample) |
| ES (1) | ES2634627T3 (enExample) |
| HR (1) | HRP20171076T1 (enExample) |
| HU (1) | HUE032863T2 (enExample) |
| IL (1) | IL240290B (enExample) |
| LT (1) | LT2953944T (enExample) |
| MX (1) | MX364486B (enExample) |
| PL (1) | PL2953944T3 (enExample) |
| PT (1) | PT2953944T (enExample) |
| RS (1) | RS56331B1 (enExample) |
| RU (1) | RU2666899C2 (enExample) |
| SG (1) | SG11201506100XA (enExample) |
| SI (1) | SI2953944T1 (enExample) |
| WO (1) | WO2014121931A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2841452T3 (es) * | 2015-02-06 | 2021-07-08 | Merck Patent Gmbh | Macrociclos de piridazinona como inhibidores de IRAK y sus usos |
| EA039043B1 (ru) | 2015-04-22 | 2021-11-25 | Райджел Фармасьютикалз, Инк. | Пиразольные соединения и способ получения и применения данных соединений |
| MX383707B (es) * | 2015-09-18 | 2025-03-14 | Merck Patent Gmbh | Compuestos de heteroarilo como inhibidores de cinasas asociadas a receptor de interleucina-1 (irak) y usos de los mismos. |
| WO2017070708A1 (en) | 2015-10-23 | 2017-04-27 | Array Biopharma, Inc. | 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases |
| JOP20180011A1 (ar) | 2017-02-16 | 2019-01-30 | Gilead Sciences Inc | مشتقات بيرولو [1، 2-b]بيريدازين |
| JP7366031B2 (ja) | 2017-09-22 | 2023-10-20 | カイメラ セラピューティクス， インコーポレイテッド | タンパク質分解剤およびそれらの使用 |
| EP3684366A4 (en) | 2017-09-22 | 2021-09-08 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| WO2019111218A1 (en) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Novel heterocyclic compounds as irak4 inhibitors |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| EP3737666A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES |
| EP3737675A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| CN112533601B (zh) * | 2018-06-04 | 2024-08-16 | 俄亥俄州创新基金会 | Eaat2活化剂及其使用方法 |
| US11292792B2 (en) | 2018-07-06 | 2022-04-05 | Kymera Therapeutics, Inc. | Tricyclic CRBN ligands and uses thereof |
| WO2020010227A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| TWI721483B (zh) | 2018-07-13 | 2021-03-11 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒𠯤衍生物 |
| HUE063586T2 (hu) | 2018-11-06 | 2024-01-28 | Edgewise Therapeutics Inc | Piridazinon-vegyületek és alkalmazásaik |
| CN113272280B (zh) * | 2018-11-06 | 2026-01-09 | 艾知怀斯治疗学公司 | 哒嗪酮化合物及其用途 |
| AU2019376647B2 (en) | 2018-11-06 | 2025-03-06 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
| PH12021500026A1 (en) | 2018-11-30 | 2022-05-11 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| JP2022515198A (ja) | 2018-12-19 | 2022-02-17 | アレイ バイオファーマ インコーポレイテッド | ＦＧＦＲチロシンキナーゼの阻害剤としての置換ピラゾロ［１，５－ａ］ピリジン化合物 |
| WO2020131674A1 (en) | 2018-12-19 | 2020-06-25 | Array Biopharma Inc. | 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer |
| BR112022003564A2 (pt) | 2019-08-30 | 2022-05-17 | Rigel Pharmaceuticals Inc | Composto, composição, composição seca por pulverização, método de preparação de uma composição seca por pulverização e método |
| US11591332B2 (en) | 2019-12-17 | 2023-02-28 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| EP4076520A4 (en) | 2019-12-17 | 2024-03-27 | Kymera Therapeutics, Inc. | IRAQ DEGRADATION AGENTS AND THEIR USES |
| WO2021231630A1 (en) * | 2020-05-13 | 2021-11-18 | Edgewise Therapeutics, Inc. | Substituted pyridazinone for use in the treatment of neuromuscular diseases |
| WO2021231615A1 (en) * | 2020-05-13 | 2021-11-18 | Edgewise Therapeutics, Inc. | Substituted pyridazinone for use in the treatment of neuromuscular diseases |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| KR20230143632A (ko) | 2020-12-30 | 2023-10-12 | 카이메라 쎄라퓨틱스 인코포레이티드 | Irak 분해제 및 이의 용도 |
| IL304907A (en) | 2021-02-15 | 2023-10-01 | Kymera Therapeutics Inc | Irak4 degraders and uses thereof |
| CN114957132A (zh) * | 2021-02-20 | 2022-08-30 | 中国科学院上海药物研究所 | 含s构型的氨基苯甲酰胺基哒嗪酮类化合物、其制备方法、药物组合物及应用 |
| WO2022187303A1 (en) | 2021-03-03 | 2022-09-09 | Rigel Pharmaceuticals, Inc. | A method for treating a disease or condition using a pyrazole compound or formulation thereof |
| CN117479935A (zh) * | 2021-04-19 | 2024-01-30 | 上海药苑生物科技有限公司 | 用于治疗川崎病的苯并噻唑和喹啉衍生物 |
| TW202309030A (zh) | 2021-05-07 | 2023-03-01 | 美商凱麥拉醫療公司 | Cdk2降解劑及其用途 |
| EP4422635A4 (en) | 2021-10-29 | 2025-11-26 | Kymera Therapeutics Inc | IRAQ4 DEGRADATION AGENTS AND THEIR SYNTHESIS |
| EP4472967A2 (en) | 2022-01-31 | 2024-12-11 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| US12384775B2 (en) | 2022-03-23 | 2025-08-12 | Rigel Pharmaceuticals, Inc. | Pyrimid-2-yl-pyrazole compounds as IRAK inhibitors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3734083A1 (de) * | 1987-10-08 | 1989-04-20 | Heumann Pharma Gmbh & Co | Benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| CA2215536A1 (en) * | 1995-03-17 | 1996-09-26 | Du Pont Pharmaceuticals Company | Cyclic urea hiv protease inhibitors |
| JP2000247959A (ja) * | 1999-02-26 | 2000-09-12 | Kowa Co | ピリダジン−３−オン誘導体及びこれを含有する医薬 |
| WO2003030902A1 (en) * | 2001-10-09 | 2003-04-17 | Tularik Inc. | Imidazole derivates as anti-inflammatory agents |
| CA2518227A1 (en) * | 2003-03-18 | 2004-09-30 | Kowa Co., Ltd | Water-soluble phenylpyridazine derivative and medicine containing the same |
| DE102006037478A1 (de) * | 2006-08-10 | 2008-02-14 | Merck Patent Gmbh | 2-(Heterocyclylbenzyl)-pyridazinonderivate |
| JP2008063265A (ja) * | 2006-09-06 | 2008-03-21 | Kyorin Pharmaceut Co Ltd | ピリダジノン誘導体及びそれらを有効成分とするｐｄｅ阻害剤 |
| NZ575410A (en) * | 2006-09-07 | 2012-03-30 | Biogen Idec Inc | 2-(1H-Indazol-3-ylamino)-1H-benzimidazole derivatives |
| DE102007025717A1 (de) * | 2007-06-01 | 2008-12-11 | Merck Patent Gmbh | Arylether-pyridazinonderivate |
| DE102007032507A1 (de) * | 2007-07-12 | 2009-04-02 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102008062826A1 (de) * | 2008-12-23 | 2010-07-01 | Merck Patent Gmbh | Pyridazinonderivate |
| BR122021014375B1 (pt) * | 2010-12-20 | 2021-11-30 | Merck Serono S.A. | Processo para preparação de derivados de indazolil triazol |
| WO2012129258A1 (en) * | 2011-03-22 | 2012-09-27 | Merck Sharp & Dohme Corp. | Amidopyrazole inhibitors of interleukin receptor-associated kinases |
| US9550794B2 (en) * | 2013-02-07 | 2017-01-24 | Merck Patent Gmbh | Macrocyclic pyridazinone derivatives |
-
2014
- 2014-02-06 ES ES14703537.2T patent/ES2634627T3/es active Active
- 2014-02-06 CN CN201480007676.1A patent/CN104968658B/zh not_active Expired - Fee Related
- 2014-02-06 US US14/766,671 patent/US9567320B2/en not_active Expired - Fee Related
- 2014-02-06 CA CA2900431A patent/CA2900431C/en not_active Expired - Fee Related
- 2014-02-06 JP JP2015556421A patent/JP6483624B2/ja not_active Expired - Fee Related
- 2014-02-06 SI SI201430307T patent/SI2953944T1/sl unknown
- 2014-02-06 EP EP14703537.2A patent/EP2953944B1/en active Active
- 2014-02-06 KR KR1020157024342A patent/KR102293952B1/ko not_active Expired - Fee Related
- 2014-02-06 HR HRP20171076TT patent/HRP20171076T1/hr unknown
- 2014-02-06 PT PT147035372T patent/PT2953944T/pt unknown
- 2014-02-06 DK DK14703537.2T patent/DK2953944T3/en active
- 2014-02-06 PL PL14703537T patent/PL2953944T3/pl unknown
- 2014-02-06 RU RU2015137757A patent/RU2666899C2/ru active
- 2014-02-06 RS RS20170743A patent/RS56331B1/sr unknown
- 2014-02-06 BR BR112015018663A patent/BR112015018663A2/pt not_active Application Discontinuation
- 2014-02-06 WO PCT/EP2014/000316 patent/WO2014121931A1/en not_active Ceased
- 2014-02-06 HU HUE14703537A patent/HUE032863T2/en unknown
- 2014-02-06 AU AU2014214321A patent/AU2014214321B2/en not_active Ceased
- 2014-02-06 MX MX2015010125A patent/MX364486B/es active IP Right Grant
- 2014-02-06 LT LTEP14703537.2T patent/LT2953944T/lt unknown
- 2014-02-06 SG SG11201506100XA patent/SG11201506100XA/en unknown
-
2015
- 2015-08-02 IL IL240290A patent/IL240290B/en active IP Right Grant
-
2016
- 2016-11-23 US US15/360,288 patent/US20170071936A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016508505A5 (enExample) | ||
| RU2015137757A (ru) | Производные пиридазинон-амидов | |
| HRP20171302T1 (hr) | Makrociklički derivati piridazinona | |
| JP2013510825A5 (enExample) | ||
| IL226912A (en) | The history of triazole, their preparation and their pharmaceutical preparations | |
| JP2019031560A5 (enExample) | ||
| RU2015107552A (ru) | Бивалентные ингибиторы ингибиторов белков апоптоза и терапевтические способы их применения | |
| JP2017538773A5 (enExample) | ||
| RU2013144579A (ru) | Ингибиторы киназы mst1 и способы их применения | |
| JP2015528447A5 (enExample) | ||
| HRP20191430T1 (hr) | Spojevi heteroarila kao inhibitori btk i njihove uporabe | |
| JP2020537657A5 (enExample) | ||
| JP2017531002A5 (enExample) | ||
| JP2011526244A5 (enExample) | ||
| JP2016505019A5 (enExample) | ||
| CN108601952B (zh) | 雷公藤内酯的葡萄糖缀合物、类似物及其用途 | |
| JP2013537203A5 (enExample) | ||
| JP2013507423A5 (enExample) | ||
| JP2016040288A5 (enExample) | ||
| JP2017538721A5 (enExample) | ||
| PH12017501989A1 (en) | Heteroaryl derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition for preventing or treating diseases associated with pi3 kinases, containing same as active ingredient | |
| JP2016506960A5 (enExample) | ||
| JP2009526034A5 (enExample) | ||
| JP2017514910A5 (enExample) | ||
| JP2013514980A5 (enExample) |